You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
|
|---|---|
| Published in |
PLOS ONE, January 2013
|
| DOI | 10.1371/journal.pone.0054522 |
| Pubmed ID | |
| Authors |
Ling-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, Mei-Yi Michelle Chan, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Andrea Li-Ann Wong, Ying-Kiat Zee, Robert Lim, Soo-Chin Lee, Paul C. Ho, How-Sung Lee, Anthony Chan, Sherry Ansher, Mark J. Ratain, Boon-Cher Goh |
| Abstract |
Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pathway of metabolism of belinostat. The pharmacokinetics of belinostat in liver cancer patients were characterized by rapid plasma clearance of belinostat with extensive metabolism with more than 4-fold greater relative systemic exposure of major metabolite, belinostat glucuronide than that of belinostat. There was significant interindividual variability of belinostat glucuronidation. The major pathway of metabolism involves UGT1A1-mediated glucuronidation and a good correlation has been identified between belinostat glucuronide formation and glucuronidation of known UGT1A1 substrates. In addition, liver microsomes harboring UGT1A1*28 alleles have lower glucuronidation activity for belinostat compared to those with wildtype UGT1A1. The main metabolic pathway of belinostat is through glucuronidation mediated primarily by UGT1A1, a highly polymorphic enzyme. The clinical significance of this finding remains to be determined. |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 40 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 22% |
| Other | 6 | 15% |
| Student > Bachelor | 5 | 12% |
| Student > Master | 5 | 12% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 3 | 7% |
| Unknown | 9 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 20% |
| Biochemistry, Genetics and Molecular Biology | 7 | 17% |
| Chemistry | 6 | 15% |
| Agricultural and Biological Sciences | 4 | 10% |
| Medicine and Dentistry | 3 | 7% |
| Other | 3 | 7% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2013.
All research outputs
#15,266,089
of 22,701,287 outputs
Outputs from PLOS ONE
#130,079
of 193,818 outputs
Outputs of similar age
#182,094
of 282,165 outputs
Outputs of similar age from PLOS ONE
#3,178
of 5,012 outputs
Altmetric has tracked 22,701,287 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 193,818 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,165 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5,012 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.